HyClone™ cell culture media, sera, and process liquids, now part of GE Healthcare.
Commenting on the acquisition, Kieran Murphy, President and CEO of GE Healthcare’s Life Sciences business says, “GE Healthcare has built a world-class set of technologies for the life sciences sector, and these new businesses will strongly enhance our current offerings. As well as providing us with new tools for drug discovery and biomedical research, our customers will benefit straight away from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. Through this acquisition we immediately expand our cell culture media and sera production capabilities in Asia, the Americas and Europe, enabling us to offer the biopharmaceutical industry greater confidence in the security of supply of a key part of their production process”.
With the HyClone capabilities, GE Healthcare delivers validated solutions for life science research through biopharmaceutical manufacturing. We offer an extensive line of high-quality classical and specialty media, sera, reagents and supplements for your cell culture needs. With manufacturing sites across the world – including a new powder media manufacturing facility in Singapore - we provide efficient, custom solutions.